An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

With the pan­dem­ic cap­tur­ing head­lines around the world, one of the big ques­tions in bio­phar­ma is whether or not the in­evitable dis­rup­tions caused by the out­break will rip­ple — or tear — through drug R&D plans.

So far, there have been few re­ports of any in­ter­rup­tions in clin­i­cal tri­als out­side of Chi­na, where the hos­pi­tal-based sys­tem of drug re­search is tak­ing an ob­vi­ous beat­ing as peo­ple steer clear of hos­pi­tals. But the prospect that the pan­dem­ic will in­evitably have an im­pact is hard to ig­nore.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.